Welcome to BioSeeker Group!

The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics

Additional Information

Published Date Apr 1, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 163
PDF Fact Sheet View Fact Sheet for the report The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,300.00

Quick Overview

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics.

    To find out more about The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes.

Research highlights

The second wave of therapeutic antibody technologies, encompassing optimized full size, fully human antibodies as well as the bits and pieces of individual antibody fragments and alternative binding domains/scaffolds is driving the formation of innovative technology platforms. While biotechs have led the race towards the discovery of novel technologies, big pharma has taken over the reigns for the development of many of these future therapeutic drugs.

In this report, BioSeeker Group has surveyed and categorized the technology platform status of over 100 companies and identified over 150 unique platforms that are shaping the current and future pipeline of monoclonal antibody therapeutics.

Scope of this report:

  • A single source for market wide competing monoclonal antibody technologies in oncology
  • Thorough examination of the leading cancer therapeutic antibody technologies
  • The race towards the next generation of therapeutic antibodies
  • Competing platforms for expression, delivery, and modification of antibodies

This report will:

  • improve your competitor analysis
  • allow you to assess the strengths/weaknesses of competing technologies
  • outline R&D alignments
  • allow you to assess the direction of future technologies

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables
5 Cancer Antibodies: The Growth Engine of the Pharmaceutical Market
5.1 Where We Stand Today
5.2 The Current Antibody Cancer Pipeline of Big Pharma and Biotech
5.3 Recent Changes in the Competitive Landscape of Monoclonal Antibody Technologies
5.3.1 Big Pharma’s Race for Monoclonal Technologies
5.3.2 The Race to the First Approved Miniature Antibody
5.4 Technology Platform Approaches to Monoclonal Antibody Therapeutics
5.5 Drug Discovery and Development Platforms
6 Monoclonal Antibody Technologies- Protein Engineering and Library Platforms
6.1 From Mouse to Human Mabs
6.2 Human Antibodies from Transgenic Mice
6.3 Library Display Platforms
6.4 Antibodies Blown to Bits: From Full Length to Fragments
7 Classification of Technology Platforms by Monoclonal Antibody Specifics
7.1 Monoclonal Antibody Sources
7.1.1 B cells
7.1.2 Plasma
7.1.3 Cancer Stem Cells and Tumor Tissue
8 Active Immunotherapeutic Platforms Using Monoclonal Antibodies
8.1 Antigen Presenting Cells/Dendritic Cells
8.2 T cells
9 Monoclonal Immuoconjugates: Strategies and Platforms
9.1 Cytotoxin-Conjugated Antibody Platforms
9.2 Radioisotope-Conjugated Antibody Platforms
9.3 Antibody-Linker Platforms
9.4 Vasculature-Targeting Platforms
10 Monoclonal Antibody Expression Platforms
10.1 Mammalian Cell, Bacterial and Hybridoma Platform Technologies
10.2 Plant and Animal Platforms of Antibody Production
10.3 Monoclonal Antibody Processing Platforms
11 Monoclonal Antibody Platforms for Non-Protein Targets
11.1 Monoclonal Antibody Platforms for Carbohydrate
11.2 Monoclonal Antibody Platforms for Lipid
12 Post-Translational Modification Platforms
12.1 Glycosylation modification
13 Novel Strategies for Monoclonal Antibody Delivery
13.1 Gene Delivery and Transfer Technologies
13.2 Epidermal Delivery
14 Monoclonals Based on Non-IgG1 Immunoglobulin Structures
15 Alternative Non-Antibody Protein Binding Technologies
16 Monoclonal Antibody Technology Profiles (Truncated list)
16.1 AbGenomics
16.1.1 AbProt™
16.98.1 Human Engineering™ Technology HE™ technology
16.98.2 Microbial Expression Technology
18 Technology Platform Index
19 Company Index


4.1 List of Boxes
Box 1: Desirable Immunogenicity from a Murine Antibody
Box 2: mAb Competition for CD200
Box 3: Using mAb Fragments to Bind Intracellular Targets
Box 4: Cancer Stem Cells: A New Paradigm in Cancer Therapeutics
Box 5: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies


4.2 List of Figures
Figure 1: Developmental Status of the Antibody-based Pharmaceutical Pipeline in Oncology
Figure 2: Top 10 Big Pharma Cancer mAb Pipeline
Figure 3: Top 10 Biotech Company Cancer mAb Pipeline
Figure 4: Investigator Country of Origin
Figure 5: Company Breakdown by Platform Classification


4.3 List of Tables
Table 1: Monoclonal Antibody Therapeutics Approved for Cancer Indications
Table 2: Recent Noteworthy Acquisitions and Mergers in the mAb-based Oncology Therapeutic Market
Table 3: TechPlatforms of Investigators Involved in Monoclonal Antibody Therapy of Cancer
Table 4: Selected Companies and their Antibody Species Specificity
Table 5: Pipeline of the Four Investigators with Transgenic Mouse Technology
Table 6: Library Display Platform Technologies
Table 7: Full Size Antibodies vs Antibody Fragments
Table 8: Research Platforms for Cancer Immunotherapy using Antibody Fragments/Formats
Table 9: Developmental Stage of Selected Bispecific Antibodies
Table 10: Developmental Stage of Selected Trispecific Antibodies
Table 11: Human Source Material for Monoclonal Antibody Platforms
Table 12: Monoclonal Antibody Technology Platforms for Immune Cell Activation
Table 13: Monoclonal Antibody Immunoconjugates Aprroved for Cancer Indications
Table 14: Monoclonal Antibody Immunoconjugation Technologies
Table 15: Radioisotope Platforms for mAb Technology
Table 16: Technology Platforms Categorized by mAb-based Expression System
Table 17: Non-Protein Targets of Monoclonal Antibody Platforms
Table 18: Technology Platforms for Post-Translational Modification of Monoclonal Antibodies
Table 19: Technology Platforms Specific for mAb Delivery
Table 20: Company Platforms Based on Non-IgG1 Immunoglobulin Structures
Table 21: Selected Companies with Cancer-Targeting Protein Therapeutics Based on Non-IgG Domains

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics.
    To find out more about The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


New Concepts in Cancer Therapeutics
There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents.... Learn More


Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. Learn More

Other selected research from the 'Oncology' category:


EGFR1 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 554 companies plus partners who are today developing 852 EGFR1 pathway targeting drugs in 3067 developmental projects in cancer across 295 different targets. In addition, there are 5 suspended drugs and another 379 drugs where development has been ceased. Learn More


Triple Analysis: Breast Cancer, Colorectal Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Targeted' category:


Cancer Antibodies: Competitive Positioning for Success
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you. Learn More


Triple Target Atlas in Oncology Drug Development
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More